ES2135934T3 - Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. - Google Patents

Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Info

Publication number
ES2135934T3
ES2135934T3 ES96937390T ES96937390T ES2135934T3 ES 2135934 T3 ES2135934 T3 ES 2135934T3 ES 96937390 T ES96937390 T ES 96937390T ES 96937390 T ES96937390 T ES 96937390T ES 2135934 T3 ES2135934 T3 ES 2135934T3
Authority
ES
Spain
Prior art keywords
group
ilo
rent
fenile
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937390T
Other languages
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2135934T3 publication Critical patent/ES2135934T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

LA INVENCION SE REFIERE A COMPUESTOS QUE RESPONDEN A LA FORMULA GENERAL (I), DONDE: R 1 REPRESENTA UN GRUPO (C SUB ,1 C 4 ) ALQUIL O (C 3 - C 7 ) CICLOALQUILMETIL; X 1 REPRESENTA UN ATOMO DE HIDROGENO O DE HALOGENO, O UN GRUPO (C 1 - C 4 ) ALCOXI, O BIEN OR 1 Y X 1 REPRESENTAN JUNTOS UN GRUPO CON LA FORMULA - OCH 2 O -, O(CH 2 ) 2 -, - O(CH 2 ) 3 -, O(CH 2 ) SU B,2 O - O - O(CH 2 ) 3 O -; X 2 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO AMINO; X 3 REPRESENTA UN ATOMO DE HIDROGENO O DE HALOGENO; Y R 2 ES O BIEN UN ATOMO DE HIDROGENO, O BIEN UN GRUPO (C 1 - C 6 ) ALQUIL EN SU C ASO SUSTITUIDO, O BIEN UN GRUPO FENIL (C 1 C 4 ) ALQUIL EN SU CASO SUSTITUIDO EN EL NUCLEO FENIL, O BIEN UN GRUPO FENIL (C 2 - C 3 ) ALCENIL, O BIEN UN GRUPO FENOXI (C SUB,2 - C 4 ) ALQUIL, O BIEN UN GRUPO CICLO (C 3 - C7 ) ALQUILMETIL, O BIEN UN GRUPO 2,3 - DIHIDRO - 1H - IND EN - 1 - ILO O 2,3 - DIHIDRO - 1H - INDEN - 2 - ILO, O BIEN UN GRUPO DE FORMULA GENERAL - (CH 2 ) N CO - Z, EN LA QUE N REPRESENTA UN NUMERO DE 1A 6 Y Z UN GRUPO PIPERIDIN - 1 - ILO O 4 - (DIMETILAMINO) PIPERIDIN - 1 - ILO. ESTOS COMPUESTOS PUEDEN UTILIZARSE PARA EL TRATAMIENTO Y LA PREVENCION DE DESORDENES EN LOS QUE ESTEN IMPLICADOS LOS RECEPTORES 5 HT 4 Y /O H 3 , EN PARTICULAR EN EL SISTEMA NERVIOSO CENTRAL, EL SISTEMA GASTROINTESTINAL, EL APARATO URINARIO INFERIOR O EL SISTEMA CARDIOVASCULAR.
ES96937390T 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. Expired - Lifetime ES2135934T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ES2135934T3 true ES2135934T3 (es) 1999-11-01

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937390T Expired - Lifetime ES2135934T3 (es) 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Country Status (30)

Country Link
US (1) US5929089A (es)
EP (1) EP0863897B1 (es)
JP (1) JP4263240B2 (es)
CN (1) CN1077891C (es)
AR (1) AR004708A1 (es)
AT (1) ATE181328T1 (es)
AU (1) AU707325B2 (es)
BG (1) BG63463B1 (es)
BR (1) BR9611311A (es)
CA (1) CA2236357C (es)
CO (1) CO4770968A1 (es)
CZ (1) CZ287268B6 (es)
DE (1) DE69602970T2 (es)
EE (1) EE03487B1 (es)
ES (1) ES2135934T3 (es)
GR (1) GR3030823T3 (es)
HK (1) HK1016165A1 (es)
HU (1) HUP0001168A3 (es)
IL (1) IL124364A (es)
MX (1) MX9803696A (es)
NO (1) NO309606B1 (es)
NZ (1) NZ321626A (es)
PL (1) PL186204B1 (es)
RU (1) RU2167160C2 (es)
SI (1) SI0863897T1 (es)
SK (1) SK282335B6 (es)
TR (1) TR199800827T2 (es)
TW (1) TW371303B (es)
UA (1) UA50748C2 (es)
WO (1) WO1997017345A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
EP0980370A1 (fr) * 1997-05-06 2000-02-23 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6664286B1 (en) 1998-09-18 2003-12-16 Alcon Manufacturing, Ltd. Serotonergic 5ht2 agonists for treating glaucoma
CN1461216A (zh) * 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
PL360886A1 (en) 2000-08-08 2004-09-20 Ortho-Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines
PT1311482E (pt) 2000-08-08 2007-04-30 Ortho Mcneil Pharm Inc Ariloxipiperidinas não imidazólicas como ligandos do receptor h3
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
DE60234616D1 (de) * 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
DE60237528D1 (de) 2001-09-14 2010-10-14 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
EP1461030A4 (en) 2001-12-14 2005-06-01 Alcon Inc AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP2233470B1 (en) * 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
ES2375872T3 (es) 2006-05-29 2012-03-07 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina.
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CN103380131B (zh) 2011-09-19 2015-12-02 苏文生命科学有限公司 作为5-ht4受体配体的杂芳基化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510283A (ja) * 1991-08-20 1994-11-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４レセプター拮抗薬
CZ283619B6 (cs) * 1991-09-12 1998-05-13 Smithkline Beecham P.L.C Použití derivátů kyseliny benzoové pro výrobu farmaceutických prostředků, deriváty kyseliny benzoo vé, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
JPH07503480A (ja) * 1992-02-06 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４拮抗薬としてのベンゾピラン，ベンゾチオピランおよびベンゾフラン誘導体
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
JP2000500125A (ja) 2000-01-11
CN1202169A (zh) 1998-12-16
EE03487B1 (et) 2001-08-15
NO309606B1 (no) 2001-02-26
UA50748C2 (uk) 2002-11-15
PL326671A1 (en) 1998-10-12
JP4263240B2 (ja) 2009-05-13
CA2236357A1 (en) 1997-05-15
DE69602970T2 (de) 2000-01-20
TR199800827T2 (xx) 1999-02-22
BR9611311A (pt) 1999-06-29
SI0863897T1 (en) 1999-10-31
PL186204B1 (pl) 2003-11-28
BG102412A (en) 1999-08-31
HUP0001168A3 (en) 2001-07-30
BG63463B1 (bg) 2002-02-28
CN1077891C (zh) 2002-01-16
MX9803696A (es) 1998-09-30
IL124364A (en) 2001-08-08
HUP0001168A2 (hu) 2001-04-28
NZ321626A (en) 1998-10-28
CA2236357C (en) 2006-10-17
CZ287268B6 (en) 2000-10-11
NO982092L (no) 1998-06-29
WO1997017345A1 (fr) 1997-05-15
SK59998A3 (en) 1998-11-04
AU707325B2 (en) 1999-07-08
AR004708A1 (es) 1999-03-10
US5929089A (en) 1999-07-27
EE9800155A (et) 1998-12-15
ATE181328T1 (de) 1999-07-15
IL124364A0 (en) 1998-12-06
NO982092D0 (no) 1998-05-07
CZ142198A3 (cs) 1998-08-12
HK1016165A1 (en) 1999-10-29
AU7500196A (en) 1997-05-29
SK282335B6 (sk) 2002-01-07
DE69602970D1 (de) 1999-07-22
GR3030823T3 (en) 1999-11-30
RU2167160C2 (ru) 2001-05-20
CO4770968A1 (es) 1999-04-30
EP0863897A1 (fr) 1998-09-16
EP0863897B1 (fr) 1999-06-16
TW371303B (en) 1999-10-01

Similar Documents

Publication Publication Date Title
ES2135934T3 (es) Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
SV2003000882A (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas ref.pca428-01cfp/bb
ES2162933T3 (es) Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).
PA8491101A1 (es) Derivados de 4-fenil-piridin.
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
AR035793A1 (es) Compuesto de ciclopropilindol, formulacion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para la preparacion de compuestos intermediarios para su sintesis
NO306945B1 (no) Nye gastrin og CCK-reseptorligander farmasoeytisk preparat inneholdende slike og anvendelse derav
FI75559C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-aminopropoxiarylderivat.
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
EA200100535A1 (ru) Цементирующая композиция и ее применение для цементирования нефтяных скважин или подобных сооружений
MXPA00010060A (es) Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
PT86980A (pt) Process for preparing benzodiazepine analogs
EA200101223A1 (ru) Новые соединения, их применение и получение
MXPA05008118A (es) Derivados de oxima halogenados y el uso de los mismos como acidos latentes.
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
PA8556301A1 (es) Compuestos pirimidina de anillo fusionado alquinilado
ES2163417T3 (es) Derivados de benzamida.
SK96995A3 (en) 3-hydroxyanthranile acid derivatives, methods and intermediates products for their production, pharmaceutical compositions and their use
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
DK0626381T3 (da) Fremstilling af form 1 ranitidinhydrochlorid
FI934621A (fi) Pyrazolo 4,3-c pyridiner, foerfarande foer framstaellning av dessa och anvaendning av dessa som serotoninaoterupptagningsinhibitorer
DE69226119D1 (de) Cholecystokininantagoniste
DE69911632D1 (de) Contulakin-g, analoga davon und deren verwendung
ES2171306T3 (es) Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros.
SE8305307D0 (sv) Sulfurerade bensylidenderivat

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19981001

FG2A Definitive protection

Ref document number: 863897

Country of ref document: ES